Kainos Medicine 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases   2 Products   0 Trials   8 News 
  • ||||||||||  KM023 / Kainos Medicine
    Predicting drug?drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling (Virtual) -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_342;    
    The developed PBPK model characterized the opposite effect-mediated DDIs between RFP and INH on metabolisms of ANV, accurately predicting a narrowed therapeutic window when ANV 150 mg daily was co-administered with RFP plus INH. A change in ANV dosing regimen from 150 to 225 mg was predicted to mitigate the effect of the DDIs on the Cmax and Ctrough of ANV, maintaining plasma concentration levels above the therapeutic threshold but well below the safety margin.
  • ||||||||||  fluconazole oral / Generic mfg.
    Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adults (Virtual) -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_339;    
    Co-administration of ainuovirine with fluconazole significantly increased ainuovirine systemic exposure, whereas ainuovirine did not appear to affect fluconazole exposure. Therefore, it is recommended that the ainuovirine dose be halved (i.e. 75 mg) when co-administered with strong CYP2C19 inhibitors, including fluconazole.
  • ||||||||||  KM-819 / Kainos Medicine
    Trial completion date, Trial termination:  Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA) (clinicaltrials.gov) -  Sep 20, 2024   
    P2,  N=68, Terminated, 
    Therefore, it is recommended that the ainuovirine dose be halved (i.e. 75 mg) when co-administered with strong CYP2C19 inhibitors, including fluconazole. Trial completion date: Nov 2024 --> Aug 2024 | Recruiting --> Terminated; Sponsor has decided to withdraw the study due to safety issue and re-initiate with a new clinical study
  • ||||||||||  Undisclosed HBV therapeutic / Kainos Medicine, Institut Pasteur Korea
    Biomarker, Journal:  Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion. (Pubmed Central) -  Sep 21, 2022   
    These studies, involving RT-qPCR and ELISA, suggest that Rh4/LMV combinations in particular act synergistically to inhibit the secretion of HBV particles and HBsAg. Therefore, on the assumption that appropriate in vivo data are in future agreement, Rh4, in particular, might be used in combination with nucleoside/nucleotide analogues (NUCs) to devise an effective, cost-efficient combination therapy for the treatment of patients with CHB infections.
  • ||||||||||  Undisclosed HBV therapeutic / Kainos Medicine, Institut Pasteur Korea
    Journal:  Determination of infectious hepatitis B virus particles by an end-point dilution assay identifies a novel class of inhibitors. (Pubmed Central) -  Feb 19, 2022   
    Furthermore, the assay was validated using serially diluted lamivudine, an HBV replication inhibitor, inhibiting HBV DNA secretion and infectious viral progeny by approx...Interestingly, we identified dexmedetomidine (DMM), an alpha-2 adrenergic agonist, inhibiting the secretion of infectious viral progeny by approx...We identified DMM as a novel inhibitor that exclusively interferes with the secretion of infectious HBV particles without affecting the secretion of HBV genomes. This end-point dilution assay enables the precise determination of the number of infectious HBV particles, assessment of the specific infectivity and stability of HBV particles, and identification of novel classes of HBV inhibitors.
  • ||||||||||  undisclosed HBV therapeutic / Kainos Medicine, Institut Pasteur Korea
    Review, Journal:  Inclusion of hepatitis C virus testing in National Health Screening to accelerate HCV elimination in South Korea. (Pubmed Central) -  Nov 18, 2021   
    The final decision to include HCV antibody test in National Health Screening will be made based on results of the pilot study in 2020. To eliminate hepatitis B & C by 2030 in South Korea, the KDCA established a comprehensive viral hepatitis control and management system in 2020 with the interim goal of achieving an antibody positive rate of 0.3% and treatment rate of 90% by 2025.
  • ||||||||||  KM023 / Kainos Medicine
    Preclinical, Journal:  The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro. (Pubmed Central) -  Sep 29, 2021   
    To eliminate hepatitis B & C by 2030 in South Korea, the KDCA established a comprehensive viral hepatitis control and management system in 2020 with the interim goal of achieving an antibody positive rate of 0.3% and treatment rate of 90% by 2025. ACC007 exhibits potent antiviral activity alone or with 3TC and TDF, and exerts synergistic effect against all HIV strains used in our investigation in vitro.
  • ||||||||||  undisclosed HBV therapeutic / Kainos Medicine, Institut Pasteur Korea
    Journal:  Molecular basis of the interaction of the human tyrosine phosphatase PTPN3 with the hepatitis B virus core protein. (Pubmed Central) -  Aug 19, 2021   
    We identified a pool of human PBM-containing proteins that might interact with PTPN3 in cells and that could be in competition with the HBc PBM during infection, and we also identified potential cellular partners of HBc through PDZ-PBM interactions. This study opens up many avenues of future investigations into the pathophysiology of HBV.
  • ||||||||||  undisclosed HBV therapeutic / Kainos Medicine, Institut Pasteur Korea
    Journal:  A new high-content screening assay of the entire hepatitis B virus life cycle identifies novel antivirals. (Pubmed Central) -  Jul 6, 2021   
    Patient-derived HBV genotype C was efficiently inhibited by fludarabine (EC 0.08 μM) and dexmedetomidine (EC 8.7 μM)...We used this system to screen drug libraries and identified novel anti-HBV inhibitors that potently inhibit HBV in various phases of its life cycle. This assay will be an important new tool to study the HBV life cycle and accelerate the development of novel therapeutic strategies.
  • ||||||||||  KM-819 / Kainos Medicine
    Trial completion:  Phase I, KM-819 in Healthy Subjects for Parkinson's Disease (clinicaltrials.gov) -  Apr 12, 2020   
    P1,  N=88, Completed, 
    DGNTD can induce apoptosis of the FLS by activating Fas/caspase-8 signaling pathway. Recruiting --> Completed